All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR congress coverage
Bookmark this article
Stay up to date with the latest developments in multiple myeloma with our live social media coverage from the the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, February 12–16, Honolulu, US.
The #MultipleMyeloma Hub will be attending #Tandem25 virtually!
— Multiple Myeloma Hub (@MM_Hub) February 11, 2025
February 12–15
Honolulu, US, and online
Watch out for our updates and live social media coverage. #mmsm @ASTCT @CIBMTR pic.twitter.com/foQCJ7FXox
CONGRESS | #Tandem25 | PRESENTATION@AlGarfall, @PennMedicine, presents results from the phase II BMT CTN 1902 Target CR trial evaluating ide-cel followed by lenalidomide maintenance in patients with #MultipleMyeloma who had sub-optimal response after an auto-HCT (N = 38). At 6… pic.twitter.com/GHakkpiGD6
— Multiple Myeloma Hub (@MM_Hub) February 16, 2025
CONGRESS | #Tandem25 | PRESENTATION@AlGarfall, @PennMedicine, presents results from the phase II BMT CTN 1902 Target CR trial evaluating ide-cel followed by lenalidomide maintenance in patients with #MultipleMyeloma who had sub-optimal response after an auto-HCT (N = 38). At 6… pic.twitter.com/GHakkpiGD6
— Multiple Myeloma Hub (@MM_Hub) February 16, 2025
CONGRESS | #Tandem25 | PRESENTATION@YiLinMDPhD, @MayoClinic, shares MRD-negativity outcomes from the phase III CARTITUDE-4 trial (NCT04181827) of cilta-cel vs SoC in patients with lenalidomide-refractory #MultipleMyeloma. At a median follow-up of 33.6 months, MRD-negativity… pic.twitter.com/xIN1auiAhF
— Multiple Myeloma Hub (@MM_Hub) February 14, 2025
Your opinion matters
2 votes - 47 days left ...
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox